Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol–lowering treatment. Data from over 25 cardiovascular...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Preiss, D, Tobert, JA, Hovingh, GK, Reith, C
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Elsevier 2020

Παρόμοια τεκμήρια

Lipid-modifying agents, from statins to PCSK9 inhibitors
ανά: Preiss, D, κ.ά.
Έκδοση: (2020)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
ανά: Sanjiv Gupta
Έκδοση: (2015-09-01)

United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8
ανά: Caleyachetty, R, κ.ά.
Έκδοση: (2021)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
ανά: K. O. Shnaider, κ.ά.
Έκδοση: (2023-12-01)

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
ανά: Konstantinos Koskinas, κ.ά.
Έκδοση: (2016-07-01)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
ανά: Christopher LaFratte, κ.ά.
Έκδοση: (2023-09-01)

Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial
ανά: Nissen, SE, κ.ά.
Έκδοση: (2016)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
ανά: Mohsin Haseeb, κ.ά.
Έκδοση: (2023-03-01)

JACC: Asia
ανά: Jian'an Wang, MD, PhD
Έκδοση: (2021-06-01)

JACC: Asia
ανά: Valentin Fuster, MD, PhD, κ.ά.
Έκδοση: (2021-06-01)

The PCSK9 decade
ανά: Gilles Lambert, κ.ά.
Έκδοση: (2012-12-01)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
ανά: Mbikay Majambu, κ.ά.
Έκδοση: (2008-06-01)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
ανά: Shuai Wang, κ.ά.
Έκδοση: (2022-10-01)

PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
ανά: Ying Xiao, κ.ά.
Έκδοση: (2022-11-01)

PCSK9 inhibitors
ανά: Baris Gencer, κ.ά.
Έκδοση: (2015-04-01)

JACC: Case Reports
ανά: Julia Grapsa, MD, PhD, κ.ά.
Έκδοση: (2019-08-01)

JACC: Case Reports
ανά: Julia Grapsa, MD, PhD, κ.ά.
Έκδοση: (2020-06-01)

JACC: Case Reports
ανά: Purvi Parwani, MBBS, MPH, κ.ά.
Έκδοση: (2020-09-01)

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
ανά: Preiss, D, κ.ά.
Έκδοση: (2016)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
ανά: Maram H. Abduljabbar
Έκδοση: (2024-11-01)

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment
ανά: Sliz, E, κ.ά.
Έκδοση: (2018)

Vision for JACC: Case Reports
ανά: Julia Grapsa, MD, PhD
Έκδοση: (2019-06-01)

Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week
ανά: Armitage, J, κ.ά.
Έκδοση: (2019)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
ανά: A. V. Blokhina, κ.ά.
Έκδοση: (2022-01-01)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
ανά: Markus Mohaupt
Έκδοση: (2016-07-01)

PCSK9 Inhibitors: The Evolving Future
ανά: Bijay Mukesh Jeswani, κ.ά.
Έκδοση: (2024-11-01)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
ανά: Naoto Kuyama, κ.ά.
Έκδοση: (2021-06-01)

Introducing JACC: Basic to Translational Science
ανά: Douglas L. Mann, MD, κ.ά.
Έκδοση: (2016-01-01)

Case report: Intensive statin and PCSK-9 inhibitor combo reduces plaque volume and stenosis in ischemic stroke patient
ανά: Weiqi Zeng, κ.ά.
Έκδοση: (2023-08-01)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
ανά: Preiss, D, κ.ά.
Έκδοση: (2016)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
ανά: Dennis T. Ko, κ.ά.
Έκδοση: (2018-11-01)

Role of PCSK9 inhibitors in the management of dyslipidaemia
ανά: Tiny Nair
Έκδοση: (2024-03-01)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
ανά: Martin Jozef Péč, κ.ά.
Έκδοση: (2023-08-01)

A Comprehensive Review of PCSK9 Inhibitors
ανά: Caroline Coppinger BS, κ.ά.
Έκδοση: (2022-05-01)

Cholesterol and stroke: role of PCSK9 inhibitors
ανά: L. Castilla-Guerra, κ.ά.
Έκδοση: (2019-04-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
ανά: A. Yu. Filatova, κ.ά.
Έκδοση: (2019-06-01)

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
ανά: Marianna Puccini, κ.ά.
Έκδοση: (2022-03-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
ανά: Blom DJ, κ.ά.
Έκδοση: (2016-05-01)

Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis
ανά: Zinan ZHAO, κ.ά.
Έκδοση: (2020-10-01)

The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy
ανά: Lillian Smith, κ.ά.
Έκδοση: (2016-03-01)